{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:16:25Z","timestamp":1761765385895,"version":"3.38.0"},"reference-count":19,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2010]]},"DOI":"10.1536\/ihj.51.399","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T06:11:50Z","timestamp":1292307110000},"page":"399-403","source":"Crossref","is-referenced-by-count":3,"title":["Risks and Benefits of Combined Use of Bucolome and Warfarin in Anticoagulation Therapy"],"prefix":"10.1536","volume":"51","author":[{"given":"Yuko","family":"Hatakeyama","sequence":"first","affiliation":[{"name":"Department of Cardio-Angiology, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Niwano","sequence":"additional","affiliation":[{"name":"Department of Cardio-Angiology, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroe","family":"Niwano","sequence":"additional","affiliation":[{"name":"Department of Cardio-Angiology, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Kosukegawa","sequence":"additional","affiliation":[{"name":"Department of Cardio-Angiology, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Cardio-Angiology, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Baglin TP, Keeling DM, Watson HG, British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006; 132: 277-85.","DOI":"10.1111\/j.1365-2141.2005.05856.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Singer DE, Chang Y, Fang MC, <i>et al<\/i>. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.","DOI":"10.7326\/0003-4819-151-5-200909010-00003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs 2008; 17: 925-37. (Review)","DOI":"10.1517\/13543784.17.6.925"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm575"},{"key":"5","unstructured":"5. Li J, Wang S, Barone J, Malone B. Warfarin pharmacogenomics. PT 2009; 34: 422-7."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. P&eacute;rez-Andreu V, Rold&aacute;n V, Gonz&aacute;lez-Conejero R, Hern&aacute;ndez-Romero D, Vicente V, Mar&iacute;n F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab 2009; 10: 632-42.","DOI":"10.2174\/138920009789375432"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jarvis S, Li C, Bogle RG. Possible interaction between pomegranate juice and warfarin. Emerg Med J 2010; 27: 74-5.","DOI":"10.1136\/emj.2007.055855"},{"issue":"10","key":"8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0090-9556(24)15043-X","volume":"27","author":"TAKAHASHI H","year":"1999","ISSN":"https:\/\/id.crossref.org\/issn\/0090-9556","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Osawa M, Hada N, Matsumoto K, <i>et al<\/i>. Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions. Int J Pharm 2005; 293: 43-9.","DOI":"10.1016\/j.ijpharm.2004.12.009"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003; 15: 213-6.","DOI":"10.1023\/B:THRO.0000011377.78585.63"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri&euml;t E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.","DOI":"10.1055\/s-0038-1651587"},{"key":"12","unstructured":"12. Ogawa S, Aizawa Y, Atarashi H, <i>et al<\/i>. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease. Circ J 2008; 72 (Suppl IV): 1601-8."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Loeliger EA. Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. Acta Haematol 1985; 74: 125-31. (Review)","DOI":"10.1159\/000206187"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost 2009; 7: 94-101.","DOI":"10.1111\/j.1538-7836.2008.03199.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kim YK, Nieuwlaat R, Connolly SJ, <i>et al<\/i>. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010; 8: 101-6.","DOI":"10.1111\/j.1538-7836.2009.03652.x"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010186"},{"issue":"5","key":"17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1248\/bpb.21.541","volume":"21","author":"TAKIGAWA T","year":"1998","ISSN":"https:\/\/id.crossref.org\/issn\/0918-6158","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Edwin SB, Jennings DL, Kalus JS. An evaluation of the early pharmacodynamic response after simultaneous initiation of warfarin and amiodarone. J Clin Pharmacol 2010; 50: 693-8.","DOI":"10.1177\/0091270009351885"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Murosaki N, Senoh H, Takemoto M. Intraluminal ureteral hematoma complicating anticoagulant therapy. Nippon Hinyokika Gakkai Zasshi 2005; 96: 564-7. (Japanese)","DOI":"10.5980\/jpnjurol1989.96.564"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/ihj\/51\/6\/51_6_399\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:54:39Z","timestamp":1740768879000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/ihj\/51\/6\/51_6_399\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.51.399","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"type":"print","value":"1349-2365"},{"type":"electronic","value":"1349-3299"}],"subject":[],"published":{"date-parts":[[2010]]}}}